| $376M | ||
| $350M | ||
| $215M | ||
| $107M | ||
| $100M | ||
| $99M |
Buys | $2,999,999 | 1 | 100 |
Sells | $0 | 0 | 0 |
| Sands Capital Life Sciences Pulse Fund II, L.P. | 10 percent owner | 1 | $3M | 0 | $0 | $3M |
Inhibikase Therapeutics, Inc. operates as a pharmaceutical firm in the clinical development stage, concentrating its efforts on pioneering treatments for Parkinson's Disease (PD) and a range of associated neurological conditions that impact both the brain and other parts of the body. The company's investigational pipeline includes IkT-148009, a small molecule designed to inhibit Abelson tyrosine kinase. This candidate aims to address not only Parkinson's disease itself but also early-stage gastrointestinal complications often experienced by PD patients, such as swallowing difficulties (dysphagia), neurologically-induced constipation, and multiple system atrophy. Additionally, Inhibikase is advancing IkT-001Pro through preclinical development. This prodrug, derived from the anti-cancer agent Imatinib, is intended to lessen typical gastrointestinal side effects while providing treatment for blood and stomach cancers. Beyond these primary compounds, the company is also pursuing various research programs focused on other neurological disorders. Inhibikase actively collaborates on research and development initiatives with several prominent academic institutions, including The Johns Hopkins University, Arizona State University, Michigan State University, and Louisiana State University. Established in 2008, Inhibikase Therapeutics, Inc. maintains its corporate headquarters in Atlanta, Georgia.
Over the last 12 months, insiders at Inhibikase Therapeutics, Inc. have bought $3M and sold $0 worth of Inhibikase Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Inhibikase Therapeutics, Inc. have bought $1.44M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Sands Capital Life Sciences Pulse Fund II, L.P. (10 percent owner) — $3M.
The last purchase of 2,068,965 shares for transaction amount of $3M was made by Sands Capital Life Sciences Pulse Fund II, L.P. (10 percent owner) on 2025‑11‑21.
| 2025-11-21 | Sands Capital Life Sciences Pulse Fund II, L.P. | 10 percent owner | 2.07M 2.6795% | $1.45 | $3M | +15.10% | ||
| 2024-10-21 | Bellini Roberto | director | 1.46M 12.071% | $1.37 | $2M | -9.46% | ||
| 2024-10-21 | Munshi Amit | director | 365,000 3.0178% | $1.37 | $500,050 | -9.46% | ||
| 2024-10-21 | Kush Arvind | director | 145,000 1.1988% | $1.37 | $198,650 | -9.46% | ||
| 2022-08-16 | Werner Milton H. | President and CEO | 5,000 0.0198% | $0.80 | $4,000 | -18.09% | ||
| 2022-05-27 | Werner Milton H. | President and CEO | 5,000 0.0207% | $0.98 | $4,880 | -21.09% | ||
| 2022-05-20 | Werner Milton H. | President and CEO | 10,000 0.0362% | $0.60 | $6,000 | +14.09% | ||
| 2022-05-19 | FRATTAROLI JOSEPH | Chief Financial Officer | 3,948 0.016% | $0.64 | $2,543 | +18.78% | ||
| 2021-11-17 | Werner Milton H. | President and CEO | 23,589 0.0935% | $1.97 | $46,558 | -51.43% |
| Sands Capital Life Sciences Pulse Fund II, L.P. | 10 percent owner | 13018965 9.8604% | $21.74M | 1 | 0 | |
| Werner Milton H. | President and CEO | 5335433 4.041% | $8.91M | 4 | 0 | <0.0001% |
| Bellini Roberto | director | 1460000 1.1058% | $2.44M | 1 | 0 | <0.0001% |
| Munshi Amit | director | 365000 0.2764% | $609,550.00 | 1 | 0 | <0.0001% |
| Kush Arvind | director | 145000 0.1098% | $242,150.00 | 1 | 0 | <0.0001% |
| FRATTAROLI JOSEPH | Chief Financial Officer | 48091 0.0364% | $80,311.97 | 1 | 0 | +18.78% |
$9,456,760 | 65 | 2.69% | $219.06M | |
$24,442,471 | 44 | -29.96% | $228.59M | |
$130,095 | 43 | 45.19% | $231.68M | |
$168,352,523 | 35 | 13.58% | $233.99M | |
$54,828,550 | 26 | -13.88% | $241.27M | |
$295,092,700 | 21 | -0.27% | $229.62M | |
$16,153,236 | 20 | -28.79% | $236.81M | |
$20,234,041 | 17 | 2.09% | $203.97M | |
$156,530,514 | 13 | 45.71% | $204.54M | |
$1,037,470 | 13 | 78.00% | $198.11M | |
$15,799,576 | 12 | -39.52% | $214.02M | |
$6,847,110 | 9 | 5.96% | $238.88M | |
Inhibikase Therapeutics, Inc. (IKT) | $2,762,881 | 8 | -10.76% | $220.49M |
$119,804,612 | 8 | -17.22% | $200.24M | |
$145,296,407 | 8 | -0.98% | $209.06M | |
$4,745,999 | 5 | -4.91% | $232.78M | |
$4,888,000 | 3 | -20.50% | $238.38M | |
$15,551,156 | 3 | 98.82% | $203.8M | |
$63,731 | 1 | -19.50% | $209.5M |
| Increased Positions | 48 | +106.67% | 52M | +93.77% |
| Decreased Positions | 17 | -37.78% | 394,329 | -0.72% |
| New Positions | 21 | New | 30M | New |
| Sold Out Positions | 2 | Sold Out | 156,339 | Sold Out |
| Total Postitions | 76 | +68.89% | 106M | +93.06% |
| Sands Capital Alternatives, Llc | $21,353.00 | 9.05% | 10.95M | 0 | 0% | 2025-09-30 |
| Soleus Capital Management, L.P. | $12,334.00 | 5.23% | 6.33M | 0 | 0% | 2025-09-30 |
| Fairmount Funds Management Llc | $11,944.00 | 5.06% | 6.13M | 0 | 0% | 2025-09-30 |
| Perceptive Advisors Llc | $10,572.00 | 4.48% | 5.42M | -10,725 | -0.2% | 2025-09-30 |
| Commodore Capital Lp | $10,525.00 | 4.46% | 5.4M | 0 | 0% | 2025-09-30 |
| Adar1 Capital Management, Llc | $10,233.00 | 4.34% | 5.25M | +125,498 | +2.45% | 2025-09-30 |
| Vanguard Group Inc | $6,383.00 | 2.71% | 3.27M | +48,969 | +1.52% | 2025-09-30 |
| Blackrock, Inc. | $5,997.00 | 2.54% | 3.08M | +347,018 | +12.72% | 2025-09-30 |
| Blackstone Inc. | $5,145.00 | 2.18% | 2.64M | 0 | 0% | 2025-09-30 |
| Nantahala Capital Management, Llc | $4,271.00 | 1.81% | 2.19M | 0 | 0% | 2025-09-30 |